Within this article, we provide evidence of the ability of claraT  to robustly identify the biologies underlying several Hallmarks of cancer. This is shown by a retrospective case study in malignant melanoma which represents poor prognostic disease (5-yr survival 15-20%). We applied claraT to the TCGA melanoma dataset to identify targetable biologies within both the study cohort and individual tumour samples.

This white paper retrospective study demonstrates how simultaneous analysis of multiple gene expression signatures (GES) (n=62 in this study) can identify robust biologies through consensus readouts. Almac’s claraT reporting solution may have value in the identification of reliable biomarkers for clinical trials and could inform combination strategies for targeting key biologies. 

*By submitting your information you acknowledge that you have read the privacy statement and you consent to our processing the data in accordance with that privacy statement. We may, from time to time, send you material relevant to your interests. If you change your mind at any time about wishing to receive material from us, you can send an email to [email protected]. Every email we send you will also include an unsubscribe link so you can unsubscribe from our marketing list. 
This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies